Compare Novavax Inc (NVAX) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Open Text Corporation — how do they compare? Novavax Inc trades at $12.31 (market cap $1.82B), while Open Text Corporation trades at $23.55 (market cap $5.61B). The key difference: Open Text Corporation is far larger — about 3.1× Novavax Inc's market cap, and Open Text Corporation pays a 4.82% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Open Text Corporation for 23 Days on average.
| NVAX | OTEX | |
|---|---|---|
Market Cap | $1.82B | $5.61B |
Volume | 6,198,505 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $12.56 | $39.69 |
52-Week Low | $6.22 | $20.01 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $1.39B | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
OTEX trades at $23.52, up 1.64% today, with a bearish technical signal despite recent earnings beats. The stock is attractively valued with a P/E of 9.01 and P/S of 1.1, supported by strong profitability margins. Recent news highlights debt restructuring and a strategic AI partnership with Cohere, while cash flow trends show operational strength but negative net cash flow.
The outlook is mixed: valuation discounts and cloud growth present opportunity, but high debt and bearish technicals pose risks. Analyst consensus is a Buy with a $28.30 target, implying potential upside, though execution on AI initiatives and debt management will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
